Cancer clinical trials in the region Nouvelle-Aquitaine
220 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
7 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
8 main criterias to confirm
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
8 main criterias to confirm
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
8 main criterias to confirm
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
7 main criterias to confirm
AstraZeneca
Phase 3
Kidney cancer
#NCT06364631
Clear cell carcinoma
Metastatic
None
0
1 or 2
Systemic Treatment-Naive
7 main criterias to confirm
Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Hospitalier François Mitterrand de Pau (Pau), Centre Hospitalier de la Côte Basque (Bayonne)
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lung cancer
#NCT06312137
NSCLC (Non-Small Cell Lung Cancer)
Localized
Locally Advanced
None
Systemic Treatment-Naive
Systemic Treatment-Naive
ALK
9 main criterias to confirm
Centre Hospitalier Universitaire Dupuytren (Limoges)
Merck Sharp & Dohme LLC
Phase 3
Colon cancer
Rectal cancer
#NCT06662786
Locally Advanced
Metastatic
None
Systemic Treatment-Naive
BRAF
HER2
KRAS G12C
KRAS non G12C
MSI/dMMR
NRAS
7 main criterias to confirm
CHU - Haut-Lévêque - Bordeaux (Pessac)
Janssen
Phase 3
Lung cancer
#NCT06472245
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Other mutation
Immunotherapy
ALK
EGFR
ROS-1
6 main criterias to confirm
Centre Hospitalier Universitaire Dupuytren (Limoges)
OSE Immunotherapeutics